- Home
- LANV vs CRBU Comparison
LANV vs CRBU Comparison
Compare LANV & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LANV | CRBU |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | China | United States |
| Employees | 2066 | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.1M | 192.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LANV | CRBU |
|---|---|---|
| Price | $1.46 | $2.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 2.8K | ★ 1.8M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.63 |
| Revenue Next Year | $3.33 | $10.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $1.04 |
| 52 Week High | $2.62 | $3.53 |
Technical Indicators
Market Signals| Indicator | LANV | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 49.43 |
| Support Level | $1.38 | $1.75 |
| Resistance Level | $1.83 | $2.31 |
| Average True Range (ATR) | 0.12 | 0.17 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 13.95 | 37.70 |
Price Performance
Historical ComparisonAbout LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the St. John segment.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.